Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06784193

Public ClinicalTrials.gov record NCT06784193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

Study identification

NCT ID: NCT06784193
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Enrollment: 180 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 16, 2024 (Actual)
Primary completion: May 30, 2027 (Estimated)
Completion: Aug 30, 2027 (Estimated)
Last update posted: Oct 5, 2026

2024 – 2027

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 11

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	Recruiting
University of Colorado	Aurora	Colorado	80045	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
University Medical Center - New Orleans	New Orleans	Louisiana	70112	Terminated
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
START - Midwest	Grand Rapids	Michigan	49546	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
The Ohio State University	Columbus	Ohio	43021	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Tennessee Oncology	Nashville	Tennessee	37203	Recruiting
START - San Antonio	San Antonio	Texas	78229	Recruiting
START - Mountain Region	West Valley City	Utah	84119	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06784193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 5, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06784193 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →